The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

EST Cathie Wood’s ARK Investment buys 120K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...

10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.84 which represents a decrease of $-0.01 or -0.07% from the prior close of $14.85. The stock opened at $14.99 and touched a low of ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.

10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's ...

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at ...